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Deficiency in HAChT and VAChT are characteristic neurochemical changes in AD. The 
purpose of the dissertation was to evaluate THA derivatives as HAChT imaging probe and 
also to develop a radiolabeled decalinvesamicol analogue as a PET VAChT imaging probe. 
In vitro [3H]HC-3 binding assay of THA, DMTA, PTAA, and MKC-231 revealed no 
affinity for HAChT. To develop as VAChT PET ligand, [77Br]OBDV was 
radiosynthesized with a radiochemical yield of 52.3-65.8% and radiochemical purity of > 
99%. The specific activity of [77Br]OBDV was found 322 ~ 405.7 GBq/μmol. In in vivo 
biodistribution studies, at 30 min post-injection, the average accumulation of [77Br]OBDV 
in cortex, striatum and cerebellum of rat’s brain was 0.52 ± 0.11% ID/g, 0.59 ± 0.05% ID/g 
and 0.56 ± 0.04% ID/g respectively. In in vivo blocking studies, (+/-)-vesamicol blocked 
regional brain uptake of [77Br]OBDV by 41%. In contrast, no blocking effects were 
observed by both the (+)-3-PPP and (+)-pentazocine. In ex vivo autoradiography, 
accumulation of [77Br]OBDV was observed in VAChT rich brain regions. Hence, OBDV 
labeled with 76Br was suggested to be a potent PET VAChT imaging probe.   
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Introduction:  
Alzheimer’s disease (AD) is the most common form of irreversible dementia and 
characterized clinically by progressive deterioration of intellectual abilities, including 
cognitive and behavioral dysfunctions. The degeneration of cholinergic neurons in the 
basal forebrain and the associated loss of the cholinergic neurotransmission in the cerebral 
cortex and other area contributed significantly to the deterioration in cognitive function in 
AD. Deficiency in high affinity choline uptake (HACU) and the loss of vesicular 
acetylcholine transporter (VAChT), are two characteristic neurochemical changes in AD. 
The HACU by HAChT in peripheral and central cholinergic nerve terminals plays a 
regulating and rate-limiting role in the intraneuronal synthesis of acetylcholine (ACh). The 
transportation of newly synthesized ACh the cholinergic synaptic vesicles is mediated by 
VAChT. Hence, radioligands which bind specifically to the HAChT or VAChT, are 
assumed to be used as a neuroimaging probe to investigate the cholinergic 
neurodegenerative process using PET or SPECT. 
Objectives:  
One of the objective of the dissertation was to evaluate MKC-231, tacirine (THA), 
and it’s corresponding 2-oxo-1-pyrrolidineacetyl derivative as HAChT imaging probe and 
also to find out the possible explanation of mode of action of HACU enhancer. For this 
reason we have synthesiszed THA, DMTA (2,3-dimethylfuran derivative of THA) and 
their corresponding 2-oxo-1-pyrrolidineacetyl derivatives, namely PTAA and MKC-231 
(Fig. 1) and evaluated the affinity of these synthesized compounds for HAChT through in 
vitro [3H]hemicholinium-3 ([3H]HC-3) HAChT binding assay.  
In 2012, Kozaka T et al., synthesized two new decalinvesamicol (DV) analogues, 
o-bromo-trans-decalinvesamicol (OBDV) and o-iodo-trans-decalinvesamicol (OIDV) and 
OBDV was found to possess higher affinity than OIDV towards VAChT and also higher 
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selectivity over sigma receptors (Table 1). Considering the benefits of using long-lived 
PET radioisotopes as imaging probe and also considering the ortho position of –Br 
substituent in OBDV, the another objective of the PhD thesis is to develop a radiobromine 
labelled OBDV (Fig. 2) as a PET radioligand.  
The dissertation can be divided in to two parts. Part A includes evaluation of 
tacirine derivatives as HAChT imaging probe and Part B involves the evaluation of 
radiobromine labeled OBDV as PET VAChT imaging probe.  
 
PART A: Evaluation of tacirine derivatives as HAChT Imaging probe. 
1  Results: 
1.1  Chemistry: 
The cyclization of 2-Amino benzonitrile (1) and 2-Amino-4,5-dimethyl-3-
furancarbonitrile (2) with cyclohexanone by means of ZnCl2 in toluene, furnished THA 
(3) and DMTA (4), respectively (Fig. 3).The acylation of THA (3) and DMTA (4) with 
methyl 2-oxo-1-pyrrolidineacetate furnished PTAA (5) and MKC-231 (6) with the yield of 
79% and 65% respectively (Fig. 4).  
1.2   In vitro HAChT [3H]HC-3 binding assay: 
The inhibition activities of THA, MKC-231 and the two newly synthesized tacirine 
derivatives, namely DMTA and PTAA were measured by displacement of a typical HAChT 
antagonist [3H]HC-3 (Kd = 19.1 nM) (Quirion R., 1987) in rats cerebral membrane. The 
percent inhibition against the binding of [3H]HC-3 to HAChT were calculated using 
GraphPad Prism v4 software (Figure 5).  
2 Discussions: 
HC-3 is an indirect acetylcholine antagonist, because it decreases the synthesis of 
acetylcholine by inhibiting the reuptake of choline by the HAChT. HC-3 showed the 
highest affinity for HAChT (IC50 = 20 nM). THA showed very insignificant inhibition 
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activity (IC50 = 1000 nM). DMTA and PTAA showed no affinity for HAChT. Though 
MKC-231 is known to enhance HACU, it also did not show any affinity for the HAChT. 
Other inhibitors like choline chloride (ChCl), Acetylcholine chloride (AChCl), 
Carbamylcholine Chloride (CaChCl) showed no binding affinity for HAChT.  
3.     Experimental 
3.1    Synthesis of tacirine (3)  
To a mixture of 2-Aminobenzonitrile (1) (2 g; 16.93 mmol) and cyclohexanone 
(14 mL; 135.44 mmol) in toluene (60 mL) placed in a round bottom flask connected to a 
Dean-Stark water separator, ZnCl2 (6.93 g; 50.79 mmol) was added. The mixture was 
refluxed for 06 hours. After that, the reaction mixture was cooled at room temperature and 
the remaining solids were treated with NaOH (2M, 70 mL). This mixture was then again 
refluxed for about another 06 hours with stirring. On cooling to room temperature, the 
reaction mixture were extracted with CHCl3. The organic layers were combined, dried over 
anhydrous MgSO4 and concentrated to dryness under reduced pressure. Purification of the 
residue by column chromatography on silica-gel by using ethyl acetate with trace Et3N 
afforded the target compound (3) (3.10 g, 92.26 %) as a yellow solid; 1H NMR δ 7.90-7.87 
(d, 1H), 7.70-7.67 (d, 1H), 7.58-7.54 (t, 1H), 7.38-7.34 (t, 1H), 4.63 (s, 2H), 3.05-3.01 (t, 
2H), 2.64-2.60 (t, 2H), 1.98-1.90 (m, 4H); 13C NMR δ 158.60, 146.58, 146.24, 128.92, 
128.40, 123.85, 119.50, 117.13, 110.44, 34.14, 23.75,22.86, 22.78. EI MS m/z 199 (M+, 
86.2). 
3.2   Synthesis of DMTA (4): 
To a mixture of 2-Amino-4,5-dimethyl-3-furancarbonitrile (2) (2.00 g; 14.69 
mmol) and cyclohexanone (12 mL; 117 mmol) in toluene (60 mL) placed in a round bottom 
flask connected to a Dean-Stark water separator, ZnCl2 (6 g; 44.00 mmol) was added. The 
mixture was refluxed for 06 hours. After that, the reaction mixture was cooled at room 
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temperature and the remaining solids were treated with NaOH (2M, 70 mL). This mixture 
was then again refluxed for about another 06 hours with stirring. On cooling to room 
temperature, the reaction mixture were extracted with CHCl3. The organic layers were 
combined, dried over anhydrous MgSO4 and concentrated to dryness under reduced 
pressure. Purification of the residue by column chromatography on silica-gel by using 
hexane: ethyl acetate (1:1) with trace Et3N afforded the target compound (4) (1.37 g, 
43.08 %) as a yellow solid; 1H NMR δ 4.35-4.30 (s, 2H), 2.89-2.85 (t, 2H), 2.47-2.45 (t, 
2H), 2.30 (s, 6H), 1.91-1.81 (m, 4H); 13C NMR δ 160.42, 151.34, 146.10, 145.67, 110.24, 
107.28, 105.22, 33.04, 29.00, 22.94, 22.89, 11.28, 10.27. EI MS m/z 217 (M+, 86.9). 
3.3   Synthesis of PTAA (5). 
To a mixture of tacirine (3) (1 g; 5.04 mmol) and DMF (50.4 mL), NaH (4.032 g; 
100.08 mmol) was added at room temperature maintaining Argon environment. After 01 
hour of stirring, methyl 2-oxo-1-pyrolidineacetate (2.03 mL; 15.12 mmol) was added to 
the reaction mixture maintaining the argon environment at room temperature. The reaction 
was kept in stirring for another one hour at room temperature. After a total of 2 hour, the 
reaction mixture were extracted with ethyl acetate. The organic layers were combined, 
dried over anhydrous MgSO4 and concentrated to dryness under reduced pressure. 
Purification of the residue by column chromatography on silica-gel by using ethyl acetate: 
ethanol (50:1) with trace Et3N afforded the target compound (5) (1.3 g, 79.75 %); 
1H NMR 
δ 8.57-8.56 (s, 1H), 7.99-7.96 (d, 1H), 7.76-7.72 (d, 1H), 7.64-7.59 (t, 1H), 7.48-7.43 (t, 
1H), 4.22 (s, 2H), 3.68-3.63 8 (t, 2H), 3.15-3.10 (t, 2H), 2.80-2.75 8t, 2H), 2.50-2.44 (t, 
2h), 2.17-2.10 (m, 2H), 1.98-1.93 (m, 2H), 1.88-1.82 (m, 2H); 13C NMR δ 176.76, 166.99, 
159.85, 146.90, 137.75, 128.83, 127.22, 126.06, 123.55, 121.95,49.01, 48.24, 33.99, 30.38, 
25.54, 22.67, 22.45, 18.25. EI MS m/z 324 (M+, 78.6). 
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3.4   Synthesis of MKC-231 (6). 
To a mixture of DMTA (4) (0.338 g; 1.56 mmol) and DMF (15.6 mL), NaH (1. 248 
g; 31.2 mmol) was added at room temperature maintaining Argon environment. After 01 
hour of stirring methyl 2-oxo-1-pyrolidineacetate (0.63 mL; 4.63 mmol) was added to the 
reaction mixture maintaining the argon environment at room temperature. The reaction 
was kept in stirring for another one hour at room temperature. After a total of 2 hour, the 
reaction mixture were extracted with ethyl acetate. The organic layers were combined, 
dried over anhydrous MgSO4 and concentrated to dryness under reduced pressure. 
Purification of the residue by column chromatography on silica-gel by using ethyl acetate 
with trace Et3N afforded the target compound (6) (0.350 g, 65%); 
1H NMR δ 8.45 (s, 1H), 
4.14 (s, 2H), 3.64-3.59 (t, 2H), 2.96-2.91(t, 2H), 2.64-2,59 (t, 2H), 2.47-43 8t, 2H), 2.32-
2.09 (m, 8H), 1.88-1.76 (m, 4H); 13C NMR δ 176.48, 167.67, 159.95, 151.65, 150.14, 
134.91, 123.50, 116.37, 108.19, 48.84, 47.71, 32.74, 30.29, 24.25, 22.69, 22.60, 18.12, 
11.58, 8.92. EI MS m/z 342 (M+, 81.4). 
4   Preparation of rat cerebral and liver membranes: 
Animal experiments were performed in compliance with the Guidelines for the Care 
and Use of Laboratory Animals at the Takara-machi Campus of Kanazawa University. 
Brain Homogenate of rats were prepared with the slight modification of previously 
described protocol of Sandberg K et al, 1985. Sprague-Dawley (SD) rats (8 weeks, male, 
250–300 g) cerebrum or livers were homogenized in ice-cold 0.32 M sucrose with a 
Teflon-glass homogenizer. The homogenate was centrifuged at 1000 × g at 4 oC for 10 
min. The resulting precipitate was removed and the supernatant was centrifuged at 20,000 
× g at 4 oC for 20 min. This crude mitochondrial pellet was resuspended in 20 vols. of ice-
cold distilled water and dispersed with the Teflon homogenizer with 1000 rpm and the 
homogenate centrifuged at 8000 × g run for 20 min. The supernatant and buffy coat were 
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collected and pelleted at 48,000 × g for 20 min. The pellet was washed 4 times in 20 vols. 
of 50 mM Glycylglycine buffer (pH 7.8) containing 200 mM NaCl by resuspending via 
Teflon homogenizer. Then the homogenate was centrifuged at 55,000 × g for about 15 min 
and the resulting pellet was again resuspended in 50 mM Glycylglycine buffer (pH 7.8) 
containing 200 mM NaCl with a Teflon homogenizer.  
5 In vitro HAChT [3H]HC-3 binding assay: 
[3H]Hemicholinium-3 (Kd = 19.1 nM) (Quirion R 1987) was used as a specific 
radioligand for the HAChT receptor. Rat cerebral membranes were added to each ice-cold 
assay tube containing [3H]HC-3 and the displacing ligands at various concentrations (1.0 
× 10-9 – 10-4) in 50 mM Glycylglycine buffer (pH 7.8) containing 200 mM NaCl in 
quadruplicate. After the addition of tissues in an ice bath, each reaction mixture in the tube 
was incubated at 25oC for 30 min. The incubation was terminated by pitting tubes into ice-
cold water followed by immediate filtration using a cell harvester through glass-microfiber 
filters (Whatman, GF/B), which were presoaked in the in 0.5% (v/v) polyethyleneimine 
for 01 h to reduce non-specific binding. The filters were washed with 50 mM Tris-HCl 
buffer (pH 7.8), and their radioactivities were counted with the liquid scintillation counter 
(Aloka, LSC-5100). 
PART B: Evaluation of radiobromine labeled decalinvesamicol derivative as VAChT 
Imaging probe. 
1. Results: 
1.1  Chemistry: Synthesis of OBDV and OTDV 
4-(2-bromophenyl) piperidine (7), the key intermediate for the synthesis of OBDV, 
was derived from ortho–bromobenzaldehyde by four-step reactions (Figure 6) (Kozaka T 
et al., 2012). Coupling reaction of 4-(2-bromophenyl) piperidine with trans-decalin-2,3-
oxide furnished OBDV(8) in 57% yield. The bromo substituent of OBDV was replaced by 
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a trimethylstannyl group with the reaction of Pd(PPh3)4 and hexamethylditin to obtain the 
corresponding precursor, o-trimethylstannyl-trans-decalinvesamicol (OTDV) (9) , for the 
radiosynthesis of [77Br]OBDV, with an yield of 65%  
1.2    Radiosynthesis and purification of [77Br]OBDV:  
[77Br]OBDV was radiosynthesized with a radiochemical yield of 52.3-65.8%. 
[77Br]OBDV was purified with reversed phase HPLC equipped with a Zorbax-ODS RX-
C18 column (9.6 mm × 250 mm) at a flow rate of 4.0 mL/min with a mobile phase of 
acetonitrile: H2O: monoethanolamine (90:10:0.2, v/v/v) at 40°C and radiochemical purity 
was found to be greater than 99%. Ultraviolet (UV) absorption was monitored at 230 nm. 
The retention time of [77Br]OBDV was found 10 min (Figure 8). The specific activity of 
[77Br]OBDV prepared by the tin-bromine exchange reaction was found to be 322 ~ 406 
GBq/μmol (9.8 ~ 10.9 Ci/μmol). 
1.3  In vivo biodistribution of [77Br]OBDV: 
    At 30 and 60 min post-injection, the average accumulation of [77Br]OBDV in all 
brain regions of interest was 0.56 ± 0.06% ID/g and 0.50 ± 0.05% ID/g, respectively (Table 
2). Blood clearance of [77Br]OBDV was also very rapid and at 2 min post-injection, the 
radioactivity in blood was 0.14 ± 0.01% ID/g. High radioactivity was observed in the 
pancreas (2.98 ± 0.33% ID/g) and small intestine (1.69 ± 0.26% ID/g) with maximum 
accumulation 60 min after injection. At 2 min post-injection, the accumulation of 
radioactivity in the lung was very high (5.57 ± 0.72% ID/g), but the radioactivity decreased 
to 1.23 ± 0.14% ID/g 60 min after injection. 
1.4   In vivo blocking studies 
With co-administration of 0.250 µmol (+/-)-vesamicol, uptake of [77Br]OBDV in 
the cerebral cortex, striatum, cerebellum, and the rest decreased to 42%, 43%, 42%, and 
45%, respectively, relative to the control (Figure 9). Tukey’s multiple comparison test in 
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conjunction with an ANOVA revealed very significant (P < 0.001 to P < 0.01) inhibition 
effect of (+/-)-vesamicol on the uptake of [77Br]OBDV in all brain regions. However, with 
co-administration of (+)-pentazocine or (+)-3-PPP, the accumulation of [77Br]OBDV in all 
four brain regions showed no significant difference from the control values.  
1.5   In vivo metabolite analysis 
The Rf value of [
77Br]OBDV as a standard on TLC using mobile phase of hexane: 
ethyl acetate: triethylamine (3:1:0.1, v/v/v) was 0.26 (Figure 10). In the brain samples, a 
strong spot of Rf value 0.26 ± 0.02 and a very weak trace spot around the starting point 
were observed on the TLC plate. In the plasma samples, only a highly polar radioactive 
metabolite around the starting point was seen on the TLC plate.   
1.6   Partition coefficient: 
 The partition coefficient of [77Br]OBDV was 2.93 ± 0.03. This result indicates 
that [77Br]OBDV has a reasonable degree of lipid solubility to penetrate the blood–brain 
barrier. 
1.7 Ex vivo autoradiography: 
 The accumulation in VAChT-rich regions of the rat brain was visualized in the 
ex vivo autoradiography experiment with [77Br]OBDV [Figure 11 (a)]. The distribution of 
[77Br]OBDV with high accumulation of the radiotracer was revealed in the cerebral cortex, 
striatum, diagonal band, hippocampus, thalamus and amygdaloidal nucleus. In the 
cerebellum, the localization of [77Br]OBDV binding was also witnessed in the molecular 
and granular cell layers, facial nucleus and trigeminal nucleus. With the co-injection of 
0.250 μmol (+/-)-vesamicol with [77Br]OBDV, no specific accumulation of the radiotracer 
was observed in any brain regions of rats [Figure 11 (b)]. 
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2. Discussion: 
The intracerebral biodistribution pattern of [77Br]OBDV (Table 2) revealed 
maximum accumulation of radioactivity (>0.6 % ID/g) at 2 min post-injection in all the 
brain regions and confirmed the rapid penetration of [77Br]OBDV through BBB. It 
indicates that [77Br]OBDV have suitable lypophilicity to be extracted in the brain.  
Initial brain uptake of [77Br]OBDV at 2 min post-injection was relatively 
homogeneous in the brain regions. This homogenous biodistribution is assumed to express 
the nonspecific binding of [77Br]OBDV reflected by cerebral blood flow in the brain. 
However, the specific brain regional accumulation of [77Br]OBDV was revealed 30 min 
after intravenous injection. The highest radioactivity distribution of [77Br]OBDV was 
observed in the striatum. Moderate to high distribution of radioactivity was also observed 
in the cortex, cerebellum and the other regions of the brain. This result indicates that 
[77Br]OBDV accumulated throughout the whole brain, which is in accordance with the 
brain regional accumulation of [125I]OIDV (Kozaka et al., 2014). 
The initial blood uptake of [77Br]OBDV was low (0.14 ± 0.01 & ID/g). The wash 
out from the blood was quite fast and at 60 min post-injection, the radioactivity in blood 
was 0.04 ± 0.01 % ID/g. The low blood uptake and fast blood clearance are advantageous 
for brain imaging.  
In the in vivo blocking studies, (+/-)-vesamicol (0.250 µmol) showed significant 
blocking effects on the regional brain distribution of [77Br]OBDV, demonstrating that 
[77Br]OBDV binds to vesamicol binding site on VAChT with high affinity (Figure 8). In 
contrast, no significant inhibition of the uptake of [77Br]OBDV in any brain region was 
observed with both the (+)-pentazocine (selective σ-1 receptor agonist) or (+)-3-PPP (σ-1 
and σ-2 receptor agonist), separately co-injected with [77Br]OBDV into the rats. This 
negligible changes in in vivo brain regional uptake of [77Br]OBDV, co-injected with 250 
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µmol of (+)-pentazocine or (+)-3-PPP, confirm that [77Br]OBDV does not significantly 
bind to σ-1 and σ-2 receptors like most vesamicol analogues do, presumably because the 
o-Br group of [77Br]OBDV prevents binding to σ-1 and σ-2 receptors but not VAChT.  
The presence of radiolabeled metabolites in the brain can have a negative 
influence on the imaging of VAChT; therefore, we examined the in vivo metabolism of 
[77Br]OBDV in the blood and brain of SD rats (60 min post-injection) using TLC (Figure 
9). Most of the radioactivity in the brain was unchanged with [77Br]OBDV, but only a polar 
metabolite of [77Br]OBDV was observed in the blood. This result indicates that the 
distribution of radioactivity in the rat brain at 60 min post-injection results only from 
[77Br]OBDV. The increased uptake of radioactivity in the pancreas or small intestine, even 
at 60 min post-injection, was assumed to be due to metabolites of [77Br]OBDV.  
As shown on the autoradiograms [Figure 10(A)], [77Br]OBDV was distributed in 
VAChT-rich regions of the rat brain, including the cerebral cortex, striatum, diagonal band, 
hippocampus, thalamus, amygdaloidal nucleus, cerebellum, and nuclei of cranial nerves at 
30 min post-injection. Regions of interests (ROIs) were placed over several brain regions 
with a reference brain atlas. Relative radioactivity concentration (RRC) on the brain 
regions were measured by using an image analysis software (Multi Gauge version 3, 
Fujifilm) and expressed as photostimulated luminescence (PSL)/area (mm2) (Table 3). The 
distribution pattern of radioactivity was heterogeneous, with the highest level in the 
striatum. The brain regional distribution results of table 2 almost accord with the RRC of 
the brain regions of table 3.  
The regional accumulation revealed from the autoradiograms of [77Br]OBDV 
were in accordance with the distribution of VAChT-rich brain regions such as pre-synaptic 
cholinergic nerve terminals, as shown in immunohistochemical studies (Ichikawa T et al., 
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1997) as well as the brain regional accumulation of [125I]OIDV (Kozaka t et al., 2014). 
VAChT exists in the pre-synapse of cholinergic nerve systems and mediates the 
transportation of acetylcholine (ACh) to the cholinergic synaptic vesicles. VAChT-rich 
presynaptic cholinergic nerve terminals were thought to be widely distributed in various 
brain regions, including the cerebral cortex, striatum, diagonal band, hippocampus, 
thalamus, amygdaloidal nucleus, cerebellum, and nuclei of cranial nerves, which was also 
revealed in the autoradiographic study of [77Br]OBDV. As a result the accumulation of 
[77Br]OBDV was observed throughout the whole brain regions in ex vivo autoradiography. 
Hence, OBDV, with a framework of DV and a halogen atom (-Br) at the ortho-
position of the 4-phenylpiperidine moiety, has the potential to be a promising PET VAChT 
imaging probe with the characteristics of high lipophilicity, low affinity for σ-1 and σ-2 
receptors and high selectivity for VAChT, in comparison with (+/-)-vesamicol and/or other 
vesamicol derivatives. 
3   Experimental 
3.1 Radiosynthesis and purification of [77Br]OBDV:  
[77Br]OBDV was radiosynthesized by the tin-bromine exchange reaction from the 
trimethylstannyl precursor, OTDV, with [77Br]Br-, HCl and chloramine-T (Figure7). 
[77Br]Br- was produced in the cyclotron facility of the biomedical imaging research center 
of Fukui University. Briefly, [77Br]Br-, (18.5 MBq/5~10 μL in EtOH) was added to a 
reaction vial containing OTDV (21.2 mM in EtOH, 50 μL), followed by the addition of 
0.1 M HCl (50 μL) and aq. chloramine T (23.7 mM in H2O, 40 μL). The reaction mixture 
was shaken for 5 min at room temperature and then incubated at 77oC for 30 min. The 
reaction mixture was quenched by the addition of Na2S2O5 (15.8 mM in H2O, 20 μL) and 
6 M NH3 (100 μL). The resultant mixture was passed through a Sep-Pack C-18 light 
column to remove unreacted water-soluble by products. After washing the Sep-Pack C-18 
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light column with an additional 15 mL H2O, the trapped [
77Br]OBDV in the column was 
eluted with 5 mL EtOH. The eluent was then concentrated by heating under N2.  
During the purification of [77Br]OBDV with HPLC, no UV peak of OBDV was 
detected because the concentration of OBDV was less than the detection limit. Then, the 
detection limit of OBDV was estimated using the different concentrations (103 μM ~ 10-5 
μM) of reference OBDV. The specific activity (SA) of [77Br]OBDV was calculated from 
the activity of the pure [77Br]OBDV and the mass of OBDV, assessed from the detection 
limit of OBDV ( 1×10-1 μM). 
3.2 In vivo biodistribution 
Animal experiments were carried out in compliance with the Guidelines for the 
Care and Use of Laboratory Animals at the Takara-machi Campus of Kanazawa 
University. For the biodistribution studies, 0.129 MBq (317.7 fmol) of [77Br]OBDV in 400 
μL of 5% ethanol/saline solution (v/v) was injected intravenously via the tail vein into SD 
rats (8 weeks, male, 250-300 g, n = 4 in each group). At 2, 30 and 60 min post-injection, 
the rats were sacrificed by decapitation under anesthesia with diethyl ether and blood 
samples were collected. The brain was removed and immediately placed on ice and 
dissected into segments consisting of four parts (cerebral cortex, striatum, cerebellum, and 
the rest). The blood, urine, brain regions, and the organs of interest (heart, lung, liver, 
spleen, pancreas, stomach, small intestine, kidney and bladder) were harvested and 
weighed. The radioactivity of each part was measured with an auto well gamma system 
(AccuFLEX γ7010; Aloka). Data were calculated as the percent of injected dose per gram 
of tissue (% ID/g). 
3.3   In vivo blocking studies 
Receptor blocking experiments were performed to evaluate the specific uptake of 
[77Br]OBDV. SD rats (8 weeks, male, 250-300 g, n = 4 in each group) were randomly 
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divided into four groups. The rats were injected with 0.111 MBq (273.4 fmol) of 
[77Br]OBDV in 400 μL of 5% ethanol/saline solution (v/v) intravenously via the tail vein 
with 0.250 µmol (+/-)-vesamicol, 0.250 µmol (+)-3-(3-hydroxyphenyl)-N-
propylpiperidine, [(+)-3-PPP], 0.250 µmol (+)-pentazocine, and none as a control. At 30 
min post-injection, the rats were sacrificed by decapitation under anesthesia with diethyl 
ether and blood samples were collected. The brain was removed and immediately placed 
on ice and dissected into segments consisting of four parts (cerebral cortex, striatum, 
cerebellum, and the rest). The four dissected brain parts were collected and weighed. The 
radioactivity of each part was measured with an auto well gamma system (AccuFLEX 
γ7010; Aloka). Analyses of the data from the blocking studies were performed using a one-
way ANOVA followed by a Tukey’s multiple comparison test (GraphPad Prism Version 4 
software). Differences were considered significant when P < 0.05. 
3.4   In vivo metabolite analysis 
In vivo metabolite analysis with [77Br]OBDV was performed by autoradiographic 
analysis of thin layer chromatography (TLC). The SD rats (8 weeks, male, 250-300 g, n = 
3) received intravenous injection of 0.400 MBq (985.2 fmol) of [77Br]OBDV in 400 μL of 
5% ethanol/saline solution (v/v) via the tail vein. At 60 min post-injection, the rats were 
sacrificed by decapitation under anesthesia with diethyl ether and blood samples were 
collected in a heparin-coated tube. The brain was removed, immediately placed on ice and 
the brain segments were harvested without the cerebellum. The blood corpuscles were 
separated by centrifugation at 15000 rpm for 15 min at 4oC. The resulting plasma (300 μL) 
was separated from the involved macromolecules (>10000 molecular weight) by 
ultrafiltration. The resulting filtrate was analyzed by TLC using mobile phase of hexane: 
ethyl acetate: triethylamine (3:1:0.1, v/v/v). The brain tissue was homogenized for 1 min 
with an ultrasonic homogenizer in acetonitrile and H2O (2:1). The brain homogenate 
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suspensions were centrifuged at 20000 × g for 20 min at 4oC. The supernatant was collected 
and separated from the involved macromolecules (>10000 molecular weight) by 
ultrafiltration. The resulting filtrate was analyzed by TLC using mobile phase of hexane: 
ethyl acetate: triethylamine (3:1:0.1, v/v/v). The TLC plates were then exposed to an 
imaging plate (BAS-IP SR 2025; Fujifilm) for 5 days (120 hrs), after which the plates were 
scanned by a BAS-5000 phosphoimager (Fujifilm). 
3.5   Determination of partition coefficient: 
The partition coefficient (log Po/w) of [
77Br]OBDV was determined by the 
standard method using n-octanol and 0.1 M phosphate buffer (pH = 7.4). Briefly, 
[77Br]OBDV was mixed with n-octanol (15 mL) and 0.1 M phosphate buffer (15 mL), in 
each (n) 50 mL centrifuge tube ( where, n = 4). Then the mixtures were vortexed for 5 min, 
followed by centrifugation of the mixture at 1000 × g for 10 min. After centrifugation, 
1mL n-octanol and 1 mL phosphate buffer were separately transferred to the polyethylene 
tube from each centrifuge tube in quadruplicate. The radioactivity of each tube was 
measured with an auto well gamma system (AccuFLEX γ7010; Aloka). The partition 
coefficient was calculated with the formula: log Po/w = log10 Co/Cw (radioactivity in n-
octanol layer/radioactivity in aqueous layer). 
3.6   Ex vivo autoradiography 
In ex vivo autoradiography, 1.00-1.58 MBq (2.46-3.89 pmol) of [77Br]OBDV in 
400 μL of 5% ethanol/saline solution (v/v) was injected intravenously into SD rats (8 
weeks, male, 250-300 g, n = 3) via the tail vein with 0.250 μmol (+/-)-vesamicol, and none 
as a control. At 30 min post-injection, the rats were sacrificed by decapitation under 
anesthesia with diethyl ether and blood samples were collected. The whole brain was 
harvested and immediately frozen in Tissue-Tek O.C.T. Compound (Sakura Finetek) at 
−78 oC. The frozen brain was cut into 20-μm-thick horizontal slices at −20 °C using a 
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cryostat microtome (HM 525 Cryostat; Thermo Scientific) and mounted on glass slides. 
The slices were then exposed to an imaging plate (BAS-IP SR 2025; Fujifilm) for 2 days, 
after which the plates were scanned by a BAS-5000 phosphoimager (Fujifilm).  
Conclusion:  
In vitro HAChT [3H]HC-3 competitive binding assay revealed no affinity of  
THA, DMTA, PTAA and MKC-231 towards HAChT. In efforts for the development of 
PET VAChT imaging probe, [77Br]OBDV was radiosynthesized with radiochemical purity 
of greater than 99%, and the radiochemical yield was 52.3 ~ 65.8%. The specific activity 
of [77Br]OBDV was found to be 322 ~ 406 GBq/μmol. In vivo, [77Br]OBDV appeared to 
bind selectively to VAChT with high affinity. Ex vivo autoradiography revealed that 
[77Br]OBDV accumulated in the corresponding VAChT-rich regions in the rat brain. Hence, 
it can be concluded that [76Br]OBDV has the potential to be a prospective VAChT PET 
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Table 1.  In vitro binding assay of vesamicol analogues (Kozaka T et al., 2012). 
Entry Compounds 
Ki (nM) 
VAChT σ-1 σ-2 
1  OIDV 20.5 ± 5.6  241.8 ± 98.9 118.8 ± 57.0 
2  OBDV 13.8 ± 1.2  150.7 ± 62.9 137.5 ± 97.4 
3  DV 13.6 ± 8.8  74.1 ± 39.9 68.3 ± 25.5 
4  vesamicol 33.9 ± 18.1  22.1 ± 3.6 86.7 ± 35.7 
5  DTG - 131.1 ± 39.2 31.7 ± 3.6 
6  pentazocine - 12.1 ± 5.0 1,880.8 ± 953.9 
7  haloperidol - 3.5 ± 0.8 51.6 ± 14.6 
 
Table 2: Biodistribution of [77Br]OBDV in rats after intravenous injection of the tracera 
 
Post injection time 
2 min    30 min   60 min 
Blood   0.14 ± 0.01     0.11 ± 0.12  0.04 ± 0.01 
Heart   2.19 ± 0.52  0.39 ± 0.03  0.27 ± 0.03 
Lung   5.57 ± 0.72  1.54 ± 0.24  1.23 ± 0.14 
Pancrease  2.10 ± 0.55  2.52 ± 0.98  2.98 ± 0.33 
Spleen   0.89 ± 0.34  1.35 ± 0.25  1.02 ± 0.23 
Kidney   2.90 ± 0.36  2.18 ± 0.27  1.68 ± 0.52 
Bladder   0.15 ± 0.04  0.19 ± 0.04  0.20 ± 0.03 
Urine   0.04 ± 0.04  0.25 ± 0.02  0.32 ± 0.24 
Small intestine  0.93 ± 0.14  1.24 ± 0.44  1.69 ± 0.26 
Stomach  0.26 ± 0.19  0.32 ± 0.28  0.22 ± 0.14 
Liver   1.04 ± 0.12  1.79 ± 0.05  1.62 ± 0.04 
Cerebral cortex  0.64 ± 0.06  0.52 ± 0.11  0.50 ± 0.05 
Striatum  0.62 ± 0.08  0.59 ± 0.05  0.53 ± 0.09 
Cerebellum  0.61 ± 0.09  0.56 ± 0.04  0.45 ± 0.05 
Others   0.61 ± 0.07  0.58 ± 0.05  0.50 ± 0.05 
aRadioactivities are expressed as % injected dose per gram tissue (% ID/g). The values 
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OIDV: R = I 


























































































































































Figure 9: The effect of inhibitors on the uptake of [77Br]OBDV. The vertical axis shows 
the mean radioactivity rate in the brain regions (cerebral cortex, striatum, cerebellum, and 
the rest) of each group co-injected with (±)-vesamicol (0.250 µmol) or (+)-pentazocine 
(0.250 µmol) or (+)-3-PPP (0.250 µmol), estimating the control ([77Br]OBDV only) as 
100%. The stars (*) in the figure indicate the significant difference between the uptake of 
[77Br]OBDV co-injected with (+/-)-vesamicol (0.250 µmol) and none as control in all the 
brain regions. A one-way ANOVA followed by a Tukey’s multiple comparison test was 
performed by GraphPad Prism Version 4 software, compared with the control. Here, *P 






















Figure 10: In vivo metabolite analysis of [77Br]OBDV in the rat brain 60 minutes after 
intravenous injection. Here, (A) & (B) indicate TLC analysis of plasma and brain samples, 



















































Figure 11: Ex vivo autoradiographic distribution of [77Br]OBDV in the rat brain at 30 min 
post-injection (A) with the control ([77Br]OBDV only); (B) co-injection of 0.250 μmol 
(+/-)-vesamicol with [77Br]OBDV in the rat brain as an inhibitor. Abbreviations: AM, 
anteromedial thalamus; AV, anteroventral thalamus; CBL, cerebellum; CPU, striatum; 
CTX, cerebral cortex; DB, diagonal band; HPC, hippocampus; PLCo, posterolateral 
cortical amygdaloidal nucleus; 5, trigeminal nucleus; 7, facial nucleus. 

